Brief: ISR HBV Investigates Program For Coronavirus
Feb 25 (Reuters) - ISR Immune System Regulation Holding AB
(publ) ISR.ST :
* SAID ON MONDAY UNIT ISR HBV BROADENS ITS DEVELOPMENT
PORTFOLIO
BY INCLUDING CORONAVIRUS AS POSSIBLE CANDIDATE FOR TREATMENT
WITH CO'S IMMUNOLID ISR50
Source text for Eikon: urn:newsml:reuters.com:*:nWkr36M61p
Further company coverage: ISR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))
Recent news on ISR Immune System Regulation Holding AB (publ)
See all newsBrief: ISR Holding Shares To Be Delisted From Nasdaq First North Growth Market
Brief: Nasdaq Stockholm Hands Over Investigation Of ISR Holding To Disciplinary Committee
Brief: ISR Immune System Regulation Holding Receives Notice Of Objection From Nasdaq
Brief: ISR FY 2022 Oper Loss Widens To SEK 205.1 Mln
Brief: ISR Signs Development Agreements With Catalent